scholarly journals Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

2020 ◽  
Vol 22 (1) ◽  
pp. 240
Author(s):  
Naoya Kitamura ◽  
Shinya Sento ◽  
Yasumasa Yoshizawa ◽  
Eri Sasabe ◽  
Yasusei Kudo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Drug Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Molecular Targeted Therapy ◽  
Future Prospects ◽  
Current Trends ◽  
Anti Cancer

In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.

scholarly journals Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

2019 ◽  
Vol 3 (4) ◽  
Author(s):  
Paul Gougis ◽  
Camille Moreau Bachelard ◽  
Maud Kamal ◽  
Hui K Gan ◽  
Edith Borcoman ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cancer Biology ◽  
Molecular Targeted Therapy ◽  
Locally Advanced ◽  
Clinical Development ◽  
Neck Squamous Cell Carcinoma

Abstract A better understanding of cancer biology has led to the development of molecular targeted therapy, which has dramatically improved the outcome of some cancer patients, especially when a biomarker of efficacy has been used for patients’ selection. In head and neck oncology, cetuximab that targets epidermal growth factor receptor is the only targeted therapy that demonstrated a survival benefit, both in the recurrent and in the locally advanced settings, yet without prior patients’ selection. We herein review the clinical development of targeted therapy in head and neck squamous cell carcinoma in light of the molecular landscape and give insights in on how innovative clinical trial designs may speed up biomarker discovery and deployment of new molecular targeted therapies. Given the recent approval of immune checkpoint inhibitors targeting programmed cell death-1 in head and neck squamous cell carcinoma, it remains to be determined how targeted therapy will be incorporated into a global drug development strategy that will inevitably incorporate immunotherapy.

scholarly journals Progress of molecular targeted therapy for head and neck cancer in clinical aspects

2021 ◽  
Vol 2 (1) ◽  
Author(s):  
Kenji Nakano
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Trials ◽  
Head And Neck Cancer ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Molecular Targeted Therapy

AbstractSince the body’s head and neck area affects many functions such as breathing, swallowing, and speaking, systemic treatments to head and neck cancer patients are important not only for survival but also for preserving functions and quality of life. With the progress that has been made in molecular targeted therapy, anti-EGFR antibody (cetuximab) and immune checkpoint inhibitors (nivolumab, pembrolizumab) have provided survival benefits to head and neck cancer patients and are approved for clinical practice. Clinical trials incorporating these new drugs for patients with locally advanced head/neck cancers are underway. However, the existing clinical evidence regarding molecular targeted drugs for head and neck cancers is based mostly on clinical trials allocated to squamous cell carcinoma patients. New targeted therapies for non-squamous cell carcinoma patients were recently reported, e.g., tyrosine kinase inhibitors for the treatment of thyroid cancers and HER2-targeted therapy for salivary gland cancers. With the goal of improving local control, molecular targeted treatment strategies as salvage local therapy are being investigated, including boron neutron capture therapy (BNCT) and near-infrared photoimmunotherapy (NIR-PIT). Herein the history and landscape of molecular targeted therapy for head and neck cancers are summarized and reviewed.

Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, Their Niche and Targeted Therapy

2020 ◽  
Vol 15 ◽  
Author(s):  
Meriç Bilgiç Küçükgüven ◽  
Betül Çelebi-Saltik
Keyword(s):  
Stem Cells ◽  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cancer Stem Cells ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Crucial Role ◽  
Tumor Therapy ◽  
Neck Squamous Cell Carcinoma

: Head and Neck Squamous Cell Carcinoma (HNSCC) is categorized as the sixth most common cancer worldwide, with an incidence of more than 830,000 cases per year and a mortality rate of 50%. Tobacco use, alcohol consumption, and Human Papillomavirus infection are the prominent risks for HNSCC. Despite significant developments in the treatment of HNSCC, a high rate of recurrences makes the clinical situation worse and results in poor survival rates. Recent perspectives demonstrate that whereas epithelial transformation plays a crucial role in cancer development, tumor surrounding microenvironment takes part in progression of cancer as well. Cancer Stem Cells (CSCs), which harbor unlimited self-renewal capacity, have a crucial role in the growth of HNSCC and this cell population is responsible for tumor recurrence unless eliminated by targeted therapy. CSCs are not only a promising target for tumor therapy, but also a crucial biomarker to determine the patients at high risk for undetermined results and disease development. Just as the bone marrow which is the niche of hematopoietic and mesenchymal stem cells, is important for stem cells maintenance. Similarly, the concept of microenvironment is also important for the maintenance of CSCs. Apart from the cell-cell interactions, there are many parameters in the cancer microenvironment that affect the development of cancer, such as extracellular regulation, vascularization, microbial flora, pH and oxygenation. The purpose of this review is to introduce HNSCC, explain the role of CSCs and their microenvironment and refer to the conventional and novel targeted therapy for HNSCC and CSCs.

scholarly journals 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma

2016 ◽  
Vol 23 (10) ◽  
pp. 2516-2527 ◽  
Author(s):  
Samuel A. Kerk ◽  
Kelsey A. Finkel ◽  
Alexander T. Pearson ◽  
Kristy A. Warner ◽  
Zhaocheng Zhang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cancer Stem Cells ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document